Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis
Cardiovascular Disease

Interventions

DRUG: Adalimumab
DRUG: Placebo

Sponsor

Jonathan Graf

Collaborators

[object Object]
[object Object]